Maryland panel names medical marijuana dispensary winners

U.S. Centers for Disease Control and Prevention

Emergent BioSolutions lands $911 million contract for anthrax vaccine

Emergent BioSolutions lands $911 million contract for anthrax vaccine

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the Centers for Disease Control and Prevention worth up to $911 million over five years to supply more than 29 million doses of its BioThrax anthrax vaccine.

In a notice of intent, the Biomedical Advanced Research and Development Authority said it also planned to order another $100 million-worth of BioThrax.

Emergent, which has a manufacturing facility in Baltimore, will deliver the order within two years of the contract award, expected in the first half of 2017. The company's stock shot up Friday, reaching a high of $33.94 per share and closing at $32.37, up nearly 19 percent.

The...

27°